Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Prognostic vs Predictive Value of ctDNA for Chemotherapy Planning and Discrepancy in Visual Presentation of Overall Survival

This letter comments on the CIRCULATE-Japan GALAXY analysis of adjuvant chemotherapy after resection of colorectal liver metastases. The authors note that an overall-survival benefit was reported in the ctDNA-defined MRD-positive subgroup (adjusted HR 0.27, 95% CI 0.08-0.88) but not in the MRD-negative subgroup (HR 0.54, 95% CI 0.10-2.88), and argue that a difference between subgroups cannot be inferred without a direct test of interaction. Related to the authors' reply by Kataoka, Yoshino, and Oki (doi 10.1001/jamaoncol.2026.4520).

JAMA OncologyPubMed 42986614DOI 10.1001/jamaoncol.2026.4514